Drug Development Institute
Accelerating innovative research to speed cures to cancer patients
The Drug Development Institute (DDI) is a biotech-like institute embedded in The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Our goal is to rapidly translate Ohio State’s most innovative research into tomorrow’s most promising cancer treatments for patients.
- Employs a combination of targeted investments, strategic management and cutting-edge drug development resources to drive projects from discovery through early drug development, thus creating high-value new drug candidates
- Enables Ohio State researchers to identify pharmaceutical/biotech company collaborators and advance their projects by cultivating relationships
- Fully leverages collaborative drug development resources
- Offers pharmaceutical and biotech partners innovative, high-value, commercially viable investment opportunities, thus fueling their pipelines and saving them research and development (R&D) costs
The DDI is a drug development organization staffed by industry-experienced scientists who work exclusively on early-stage drug development. By bringing an industry-focused perspective to all investment and management decisions, the DDI ensures that programs have a high likelihood of progressing to clinical stage development.